ArticlePediatric diabetes2025
Comorbidity of Type 1 Diabetes and ADHD: A Longitudinal Cohort Study in Males and Females From the Norwegian Childhood Diabetes Registry.
Article in Pediatric diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This study of interactions between attention-deficit hyperactivity disorder (ADHD) and type 1 diabetes has two aims. First, compare the prevalence of prescribed ADHD medications in individuals with type 1 diabetes to the general paediatric population in Norway. Second, study trajectories in mean glycated haemoglobin (HbA1c) in individuals with comorbid ADHD in comparison to individuals with type 1 diabetes only. Methods: Part 1 uses data from the Norwegian Prescription Database and register linkage between the Norwegian Childhood Diabetes Registry (NCDR) and the Norwegian Prescribed Drug Registry to obtain yearly prevalence in the general population and NCDR between 2005 and 2019. Part 2 uses data from annual controls in NCDR between 2005 and 2022. Linear mixed-effects models adjusted for age and diabetes duration were used to compare mean HbA1c in 365 individuals (66% males) with comorbid ADHD to 5,888 individuals (54% males) with type 1 diabetes only. Results: Part 1: Yearly prevalence (2009-2019) ranged from 0.02 to 0.52 percentage points higher in NCDR than in the general population. The difference was significant only for 2017. Part 2: Mean national HbA1c decreased from 2012 to 2022 but was higher in individuals with comorbid ADHD. This difference was significant from 2016 (67.6 mmol/mol [8.3%] vs. 64.5 mmol/mol [8.1%]) to 2022 (57.5 mmol/mol [7.4%] vs. 54.7 mmol/mol [7.2%]). When grouped by sex, these differences continued to be significant in males (except in 2018), but not in females. Individuals with ADHD were more likely to have experienced at least one episode of diabetic ketoacidosis (odds ratio [OR] = 1.39, 95% confidence interval [CI] [1.04, 1.86]; males: OR = 1.65, 95% CI [1.15, 2.36]; females: OR = 1.10, 95% CI [0.658, 1.83]). Conclusion: Mean national HbA1c decreased in Norway during the last decade, but continued to be higher in individuals with comorbid ADHD than in individuals with type 1 diabetes only.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.